Spike Protein an Engineered Prion Protein? – Kevin McCairn PhD

May 25, 2024 | COVID-19, Research, Treatment

Responsive Centered YouTube Video
Discussion on the spike protein as an engineered prion protein and its implications for neurological disorders.

  • Dr. Kevin McCairn is a retired systems neuroscientist and primate physiologist. • 0:00

  • The spike protein is considered an engineered prion and incapacitation agent. • 1:00

  • Amals and prons are related to protein misfolding disorders in neurological diseases. • 2:34

  • These proteins have a core property of developing a hydrophobic beta sheet core. • 3:31

  • They can trigger misfolding processes in other peptides, making the landscape complex. • 4:01

  • Specific brain regions may be affected by these protein misfolding disorders. • 4:21

Discussion on the potential engineering of the spike protein and its impact on neurological disorders.

  • MRI images showing cordate and thalamic regions, as well as inflammation in the cortex. • 04:40

  • Classification of prion disorders and their microscopic appearance. • 05:49

  • Discovery of specific peptides in neurological disorders, indicating crossover between different disorders. • 06:18

  • Introduction of prion-like concept to classical neurodegenerative disorders. • 07:08

  • Discussion on the spike protein and its potential engineering. • 09:07

Concerns raised about the spike protein in SARS-CoV-2, its potential neuroinvasive and neurotropic effects, and the presence of amalogenic epitopes.

  • SARS-CoV-2 may be a product of biowarfare research, with potential consequences. • 09:35

  • The spike protein contains amalogenic epitopes, raising concerns about its impact on the immune system. • 11:59

  • Nutrifil elastase can cause the spike protein to fragment, spreading epitopes through the body. • 13:23

Discussion on the potential engineering of spike protein as a prion protein, its implications, and concerns regarding the COVID-19 vaccines.

  • The spike protein’s binding onto is significantly longer than previous iterations of SARS and MERS. • 14:15

  • Concerns raised about the molecular structure changes and the origin of the spike protein. • 14:36

  • Research indicating the emergence of anomalous protein structures in the blood circulation due to spike protein exposure. • 15:10

  • Unusual stacking of properties observed, including resistance to enzymatic degradation mechanisms. • 15:39

  • Identification of HIV-like sequences and concerns about their presence in the spike protein. • 16:18

  • Observations of increased cellular damage and emergence of a new variant. • 17:02

  • Distribution of anomalous sequences in COVID-19 vaccines and concerns about their implications. • 18:01

Discussion on excess deaths, potential involvement of spike protein in causing prion-like propagation, and the need to address medical countermeasures industries.

  • Excess deaths not primarily due to COVID, but related to cardiovascular and neurodegenerative diseases. • 18:43

  • Significant increase in all-cause mortality in younger age groups in the past year. • 19:36

  • Hypotheses about spike protein’s involvement in Long COVID and prion-like propagation. • 20:01

  • Call to action for addressing the influence of medical countermeasures industries. • 20:54